Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of mgmt immunohistochemistry in glioblastoma

American Journal of Surgical Pathology

Volumn 37, Issue 2, 2013, Pages 264-271

  Hsu, Chih Yi ^a,b   Lin, Shih Chieh ^a,b   Ho, Hsiang Ling ^a,b   Chang Chien, Yi Chun ^a   Hsu, Sanford P C ^b,c   Yen, Yu Shu ^b,c   Chen, Ming Hsiung ^b,c   Guo, Wan You ^a,b   Ho, Donald M T ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Department of Neurology ^*  (Taiwan)

Author keywords

glioblastoma; immunohistochemistry; MGMT; prognosis

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; CHILD; DNA METHYLATION; DRUG EFFECT; FEMALE; GENETICS; GLIOBLASTOMA; HISTIOCYTE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD; PROMOTER REGION; STAINING; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; ENDOTHELIUM, VASCULAR; FEMALE; GLIOBLASTOMA; HISTIOCYTES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; STAINING AND LABELING; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84872876162     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318267b061     Document Type: Article

References (28)

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
2. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
3. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6:39-51.
4. Everhard S, Tost J, El Abdalaoui H, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 2009;11:348-356.
5. Malley DS, Hamoudi RA, Kocialkowski S, et al. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol. 2011;121:651-661.
6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
7. Felsberg J, Rapp M, Loeser S, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009;15:6683-6693.
8. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28: 2712-2718.
9. Cao VT, Jung TY, Jung S, et al. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery. 2009;65:866-875; discussion 875.
10. Hegi ME, Diserens A-C, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871-1874.
11. Karayan-Tapon L, Quillien V, Guilhot J, et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol. 2010;97:311-322.
12. Lechapt-Zalcman E, Levallet G, Dugue AE, et al. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer. 2012. Feb 22. DOI: 10.1002/cncr.27441. [Epub ahead of print].
13. Anda T, Shabani HK, Tsunoda K, et al. Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res. 2003;25:241-248.
14. Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007;25:1470-1475.
15. Preusser M, Charles Janzer R, Felsberg J, et al. Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008;18:520-532.
16. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008;16:59-65.
17. Brell M, Ibanez J, Tortosa A. O6-methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and metaanalysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer. 2011;11:35.
18. Sasai K, Nodagashira M, Nishihara H, et al. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol. 2008;32:1220-1227.
19. Macdonald DR, Cascino TL, Schold SC Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
20. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-797.
21. Mö llemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 2005;113:379-385.
22. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29-38.
23. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330-1338.
24. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13:2038-2045.
25. Capper D, Mittelbronn M, Meyermann R, et al. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol. 2008;115:249-259.
26. Fritz G, Tano K, Mitra S, et al. Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments.Mol Cell Biol. 1991;11:4660-4668.
27. Blough MD, Zlatescu MC, Cairncross JG. O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res. 2007;67:580-584.
28. Crone TM, Goodtzova K, Pegg AE. Amino acid residues affecting the activity and stability of human O6-alkylguanine-DNA alkyltransferase. Mutat Res. 1996;363:15-25.